Use of the basic form of recombinant human erythropoietin in the treatment of a patients with spinocerebellar ataxia with cag repeat mutations

A method for treating spinocerebellar ataxia (SCA) with mutations of CAG repeats type in a patient, the method comprising nasally administering to the patient a basic form of recombinant human erythropoietin (rhEPO).

A method of stratification of spinocerebellar ataxia (SCA) with mutations of CAG repeats type patients into responders or non-responders to treatment with a basic form of recombinant human erythropoietin (rhEPO) which involves administration of said rhEPO to patients in which:

• the number of CAG repeats correlates with severity of the SCA and/or,
• the number of CAG repeats correlates inversely with concentration of rhEPO in cerebrospinal fluid (CSF) of patients.

A method for treating SCA patients with mutations of the CAG repeats type wherein said treatment comprises stratifying patients into responders and non-responders to treatment by evaluating whether:

• said patient's number of CAG repeats correlates with the severity of the disease and/or,
• said patient's number of CAG repeats correlates inversely with the concentration of erythropoietin (EPO) in the cerebrospinal fluid (CSF) of said patient.